Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Perspective Therapeutics (CATX) over the last 16 years, with Q3 2025 value amounting to -$16.3 million.

  • Perspective Therapeutics' Cash from Operations fell 58401.66% to -$16.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.4 million, marking a year-over-year decrease of 1203117.82%. This contributed to the annual value of -$18.3 million for FY2024, which is 5044.02% up from last year.
  • Perspective Therapeutics' Cash from Operations amounted to -$16.3 million in Q3 2025, which was down 58401.66% from -$20.0 million recorded in Q2 2025.
  • Perspective Therapeutics' 5-year Cash from Operations high stood at $13.8 million for Q1 2024, and its period low was -$26.6 million during Q4 2024.
  • Moreover, its 5-year median value for Cash from Operations was -$7.1 million (2022), whereas its average is -$7.0 million.
  • In the last 5 years, Perspective Therapeutics' Cash from Operations surged by 45276.32% in 2021 and then tumbled by 58401.66% in 2025.
  • Perspective Therapeutics' Cash from Operations (Quarter) stood at $2.7 million in 2021, then plummeted by 327.0% to -$6.1 million in 2022, then crashed by 48.01% to -$9.0 million in 2023, then tumbled by 195.36% to -$26.6 million in 2024, then surged by 38.77% to -$16.3 million in 2025.
  • Its Cash from Operations stands at -$16.3 million for Q3 2025, versus -$20.0 million for Q2 2025 and -$21.6 million for Q1 2025.